CORDIS
EU research results

CORDIS

English EN

Regulation of red cell life-span, erythropoiesis, survival, senescence and clearance

Project information

Grant agreement ID: 675115

Status

Closed project

  • Start date

    1 September 2015

  • End date

    31 August 2019

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 896 558,64

  • EU contribution

    € 3 896 558,64

Coordinated by:

UNIVERSITAT ZURICH

Switzerland

Objective

Anaemia is the most common pathological condition affecting 1.6 billion individuals worldwide. It thus presents a serious health care problem and an economic burden. Reduction in red blood cell (RBC) number can be caused by blood loss, diet, stress conditions including endurance sport, and pathologies which are caused by primary genetic aberrations or are secondary to the malfunction of other cell types. Transfusion of RBC, which is often the only cure for severe cases of anaemia, is associated with risks such as thrombosis and transfusion reactions due to allo-immunisation. There is an unmet need to improve treatment of anaemia through early and accurate diagnosis, targeted treatment, and increased safety and effectiveness of RBC transfusion. The aim of RELEVANCE is to improve fast and cost-effective diagnosis of the underlying cause of primary anaemia, and to improve treatment options for both general and personalised medicine. We defined five key objectives: (1) to improve diagnostics of anaemia, particularly for hereditary rare forms of anaemia (RA); (2) to find novel treatments for anaemia that target RBC production, ageing and clearance; (3) to reduce premature loss of RBC following transfusion; (4) to produce cultured RBC for transfusion; (5) to monitor and optimise RBC function during sport and exercise. RELEVANCE will train 15 early stage researchers (ESR) at four SMEs and eight academic partners, two of whom are at blood supply centres and two are diagnostic centres for RA. The continuous interactions between the clinic, blood supply centers, basic research, and industry will select for the most relevant unmet medical needs, and will stimulate innovative procedures that are immediately probed for applicability and validity both in a research and a clinical setting. RELEVANCE will organize three open access summer schools, extending training beyond the ESR of the ITN sustaining the critical number of young talented professionals in the field.

Coordinator

UNIVERSITAT ZURICH

Address

Ramistrasse 71
8006 Zurich

Switzerland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 265 226,76

Participants (13)

UNIVERSITAT DES SAARLANDES

Germany

EU Contribution

€ 498 432,96

UNIVERSITY OF BRISTOL

United Kingdom

EU Contribution

€ 273 287,88

UNIVERSITA DEGLI STUDI DI PAVIA

Italy

EU Contribution

€ 258 061,32

Stichting Sanquin Bloedvoorziening

Netherlands

EU Contribution

€ 510 748,56

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands

EU Contribution

€ 255 374,28

CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Spain

EU Contribution

€ 13 770,72

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 262 875,60

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 262 875,60

ARIVIS AG

Germany

EU Contribution

€ 249 216,48

EPIGEM LIMITED

United Kingdom

EU Contribution

€ 273 287,88

NANION TECHNOLOGIES GMBH

Germany

EU Contribution

€ 249 216,48

OPTOROBOTIX APS

Denmark

EU Contribution

€ 290 081,88

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS

Spain

EU Contribution

€ 234 102,24

Partners (2)

PHAST GmbH

Germany

EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH

Germany

Project information

Grant agreement ID: 675115

Status

Closed project

  • Start date

    1 September 2015

  • End date

    31 August 2019

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 896 558,64

  • EU contribution

    € 3 896 558,64

Coordinated by:

UNIVERSITAT ZURICH

Switzerland